announcment out

Unit 2, Level 1, 320 Lorimer St,
Port Melbourne, Victoria 3207
ACN 083 866 862
7 July 2010
Strategic holding in Avexa Limited
Calzada Limited (Calzada) holds a 16.06% shareholding in Avexa Limited (Avexa). Calzadas shareholding
was acquired after Avexa announced the closure of its apricitabine (ATC) development program.
Calzada abstained from voting at yesterdays shareholder meeting of Avexa after it became clear that the
previous Board had lost the support of Avexa shareholders, and the proposed new directors decided not to
publicly state their intentions for the Company.
Calzada is seeking to engage with the new Avexa Board to understand the new Board members intentions
for the future direction of the Company. Calzada has also requested Board representation commensurate
with its position as the largest shareholder in the Company.
As a major shareholder, Calzadas focus is on ensuring that the new Board of Avexa is working in the best
interests of all shareholders to protect and enhance shareholder value.
For further information please contact:
David Franklyn
Executive Chairman
Calzada Limited
Ph: 0402 447 839